Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 277 No 7419 p365
23 September 2006

This article
Reprint   Photocopy

PDF 40K, Acrobat Reader

Letters

· NHS
· Paracetamol
· BPC
· Homoeopathy
· The Society
· Retention fee


Letters to the Editor

British Pharmaceutical Conference

New national framework is a significant move

From Mr C. Ranshaw, FRPharmS

In your leading article “We all could do better” (PJ, 9 September, p298) you expressed disappointment that the organisers of the British Pharmaceutical Conference had not done more to invite pharmacists with special clinical interests to talk about their work at the conference.

While the Royal Pharmaceutical Society was pleased that health minister Andy Burnham chose to launch the new national framework for pharmacists with special interests (PhwSIs) at the BPC, we only had short notice of his intention to do so. However the move is a significant one for the profession and attracted national media attention including a major story in the Daily Mail of 5 September.

The BPC is a flagship event for the profession and the programme included many expert practitioners who addressed the conference on a range of subjects, including pharmacy prescribing, mental health, medicine usage reviews and public health. The national framework will enable the pharmacists to help people with long-term conditions to cope with their treatment at home. Significantly David Colin-Thomé and Beth Taylor, two members of the advisory group responsible for producing the framework, were also speakers.

I am sure that those expert pharmacists who presented at the BPC this year will be among the first to undergo training and gain accreditation to enable them to become PhwSIs.

I also expect that many will return to the BPC in 2007 to share their experiences and encourage fellow pharmacists to take up the challenge.

Colin Ranshaw
Chairman of the Conference Committee
Royal Pharmaceutical Society

Send your letter to The Editor

Previous Topic (Paracetamol)
Next Topic (Homoeopathy)

Back to Top


©The Pharmaceutical Journal